• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chappell Dale sold $4,250 worth of shares (386,350 units at $0.01) (SEC Form 4)

    10/20/23 6:50:35 PM ET
    $HGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HGEN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Chappell Dale

    (Last) (First) (Middle)
    C/O OPUS EQUUM INC.
    PO BOX 788

    (Street)
    DOLORES CO 81323

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HUMANIGEN, INC [ HGEN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Scientific Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    10/18/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, $0.001 par value(1) 10/18/2023 S 34,253 D $0.011 1,041,536 I(2) By Black Horse Capital LP
    Common Stock, $0.001 par value(1) 10/18/2023 S 75,887 D $0.011 2,307,530 I(3) By Black Horse Capital Master Fund Ltd.
    Common Stock, $0.001 par value(1) 10/18/2023 S 276,210 D $0.011 8,398,871 I(4) By Cheval Holdings, Ltd.
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Chappell Dale

    (Last) (First) (Middle)
    C/O OPUS EQUUM INC.
    PO BOX 788

    (Street)
    DOLORES CO 81323

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BLACK HORSE CAPITAL LP

    (Last) (First) (Middle)
    C/O OPUS EQUUM INC.
    PO BOX 788

    (Street)
    DOLORES CO 81323

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BLACK HORSE CAPITAL MANAGEMENT LLC

    (Last) (First) (Middle)
    C/O OPUS EQUUM INC.
    PO BOX 788

    (Street)
    DOLORES CO 81323

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Black Horse Capital Master Fund Ltd.

    (Last) (First) (Middle)
    C/O OPUS EQUUM, INC.
    P.O. BOX 788

    (Street)
    DOLORES CO 81323

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Cheval Holdings, Ltd.

    (Last) (First) (Middle)
    P.O. BOX 309G, UGLAND HOUSE
    GEORGETOWN

    (Street)
    GRAND CAYMAN E9 KY1-1104

    (City) (State) (Zip)
    Explanation of Responses:
    1. This Form 4 is filed jointly by Black Horse Capital LP (the "Domestic Fund"), Black Horse Capital Master Fund Ltd. (the "Offshore Fund"), Cheval Holdings, Ltd. ("Cheval"), Black Horse Capital Management LLC ("BH Management") and Dale Chappell (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that may be deemed to collectively beneficially own more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. The filing of this Form 4 shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer he or it does not directly own.
    2. Securities owned directly by the Domestic Fund. BH Management, as the managing general partner of the Domestic Fund, may be deemed to beneficially own the securities owned directly by the Domestic Fund.
    3. Securities owned directly by the Offshore Fund.
    4. Securities owned directly by Cheval. BH Management may be deemed to beneficially own the securities owned directly by Cheval.
    BLACK HORSE CAPITAL LP By: Black Horse Capital Management LLC, its Managing General Partner By: /s/ Geoff Winkler Name: Geoff Winkler Title: Authorized Person 10/20/2023
    BLACK HORSE CAPITAL MASTER FUND LTD. By: /s/ Geoff Winkler Name: Geoff Winkler Title: Authorized Person 10/20/2023
    BLACK HORSE CAPITAL MANAGEMENT LLC By: /s/ Geoff Winkler Name: Geoff Winkler Title: Authorized Person 10/20/2023
    CHEVAL HOLDINGS, LTD. By: /s/ Geoff Winkler Name: Geoff Winkler Title: Authorized Person 10/20/2023
    By: /s/ Dale Chappell Name: Dale Chappell 10/20/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HGEN

    DatePrice TargetRatingAnalyst
    7/13/2022$13.00 → $2.00Buy → Neutral
    ROTH Capital
    7/13/2022$30.00 → $2.00Overweight → Neutral
    Cantor Fitzgerald
    7/13/2022Buy → Neutral
    H.C. Wainwright
    9/10/2021$9.00Buy → Hold
    Jefferies
    9/9/2021Outperform → Neutral
    Credit Suisse
    9/9/2021$36.00 → $28.00Buy
    H.C. Wainwright
    9/9/2021Neutral → Underweight
    JP Morgan
    8/13/2021$25.00 → $24.00Outperform
    Credit Suisse
    More analyst ratings

    $HGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

      CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix evaluable subjects, including those with high risk CMML, demonstrated clinical benefit at three months follow-upLenzilumab appears to be well-toleratedShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (NASDAQ:HGEN), Humanigen Australia Pty Ltd, (Humanigen) and the South Australian Health and Medical Research Institute (SAHMRI) today presented (poster CT085/13); the design and baseline results of the Precision Approach to Chronic Myelomono

      4/14/23 12:05:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Reports Third Quarter 2022 Financial Results

      Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strategy. The company is accelerating the development of lenzilumab in chronic myelomonocytic leukemia (CMML), a rare blood cancer, for which the PREACH-M study is already underway. The company is also contin

      11/14/22 4:01:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

      Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinical development of lenzilumab, Ifabotuzumab and HGEN005.A livestream will be available and a webcast link to a recording of the event will be posted to the "Events and Presentations" section of Humanige

      11/10/22 8:02:00 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    SEC Filings

    See more
    • Humanigen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HUMANIGEN, INC (0001293310) (Filer)

      1/8/24 5:02:09 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Humanigen Inc.

      25-NSE - HUMANIGEN, INC (0001293310) (Subject)

      10/12/23 8:19:55 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - HUMANIGEN, INC (0001293310) (Filer)

      9/14/23 4:01:46 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Financials

    Live finance-specific insights

    See more
    • Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update

      Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021. The peer-reviewed paper in The Lancet Respiratory Medicine is available via the follow link: https://doi.org/10.1016/S2213-2600(21)00494-X The associated comment in The Lancet Respiratory Medicine is available via the following link: https://doi.org/10.1016/S2213-2600(21)00539-7 Details about how to access the conference call and webcast are pr

      12/1/21 6:45:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Humanigen Inc. (Amendment)

      SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)

      2/1/23 1:21:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Humanigen Inc. (Amendment)

      SC 13D/A - HUMANIGEN, INC (0001293310) (Subject)

      3/17/22 4:28:37 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Humanigen Inc. (Amendment)

      SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)

      2/14/22 4:54:04 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Humanigen downgraded by ROTH Capital with a new price target

      ROTH Capital downgraded Humanigen from Buy to Neutral and set a new price target of $2.00 from $13.00 previously

      7/13/22 9:07:33 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Humanigen from Overweight to Neutral and set a new price target of $2.00 from $30.00 previously

      7/13/22 7:40:18 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Humanigen from Buy to Neutral

      7/13/22 7:39:46 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chappell Dale sold $4,250 worth of shares (386,350 units at $0.01) (SEC Form 4)

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      10/20/23 6:50:35 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hohneker John

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      7/29/22 6:31:06 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Buxton Cheryl

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      7/29/22 6:31:07 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

      Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Rainer Boehm as an independent director to its Board of Directors. Mr. Boehm will serve on Omega's audit and compensation committees. "Rainer's growth-oriented perspective and global strategic management experience will be invaluable to Omega in this next phase o

      9/1/22 7:00:00 AM ET
      $CLLS
      $HGEN
      $OMGA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

      Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceutical companies, as Chief Medical Officer Reports inducement grant to Dr. Truitt under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of Timothy E. Mo

      8/10/22 4:50:35 PM ET
      $AQST
      $DBVT
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations

      BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the appointment of Ken Trbovich to the newly-created role of SVP of Investor Relations, effective immediately, reporting to Timothy E. Morris, COO/CFO of Humanigen. Mr. Trbovich brings to Humanigen 20 years of experience on Wall Street as a Managing Director and Senior Analyst at several leading investment banks including Janney Montgomery Scott, MLV & Co. (now part of B. Riley), C.E. Unterberg, Towbin (now part of C

      6/7/21 8:00:00 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care